title: Effect of caffeic acid phenethyl ester on gastric acid secretion in vitro.
abstract: Caffeic acid phenethyl ester (CAPE), one of the major components of propolis (honeybee resin), has demonstrated a wide spectrum of activities including suppression of eicosanoids by inhibition of cyclooxygenase-1 and cyclooxygenase-2 enzyme activities. The aim of this study was to investigate the effect of CAPE on basal and secretagogues-stimulated gastric acid secretion in vitro. In the isolated, lumen-perfused, stomach preparation of mouse, CAPE (10-100 microM) did not affect the basal gastric acid secretion nor the secretion stimulated by histamine, pentagastrin, isobutyl methylxanthine and high levels of K+. By contrast, CAPE increased the gastric acid secretion induced by the muscarinic receptor agonist, 5-methylfurmethide (5-MEF). CAPE also inhibited the acetylcholinesterase activity in an in vitro colorimetric assay. Eserine (10 microM), a well known acetylcholinesterase inhibitor, also increased 5-MEF-stimulated acid secretion. Our results show that CAPE increases gastric acid secretion stimulated by an acetylcholine agonist receptor likely through inhibition of acetylcholinesterase activity.
authors.affiliation: Department of Experimental Pharmacology, University of Naples Federico II, Via D. Montesano 49, 80131, Naples, Italy. franborr@unina.it
authors.forename: Francesca
authors.initials: F
authors.lastname: Borrelli
authors.forename: Inmaculada
authors.initials: I
authors.lastname: Posadas
authors.forename: Raffaele
authors.initials: R
authors.lastname: Capasso
authors.forename: Gabriella
authors.initials: G
authors.lastname: Aviello
authors.forename: Valeria
authors.initials: V
authors.lastname: Ascione
authors.forename: Francesco
authors.initials: F
authors.lastname: Capasso
mesh_terms: D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D000110:Acetylcholinesterase / Q000378:metabolism; D000818:Animals; D002109:Caffeic Acids / Q000494:pharmacology*; D002800:Cholinesterase Inhibitors / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005744:Gastric Acid / Q000378:metabolism*; D005753:Gastric Mucosa / Q000378:metabolism; D005765:Gastrointestinal Agents / Q000494:pharmacology; D006632:Histamine / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009116:Muscarine / Q000031:analogs & derivatives / Q000494:pharmacology; D009543:Nifedipine / Q000494:pharmacology; D010418:Pentagastrin / Q000494:pharmacology; D010626:Phenylethyl Alcohol / Q000031:analogs & derivatives* / Q000494:pharmacology; D010830:Physostigmine / Q000494:pharmacology; D011188:Potassium / Q000494:pharmacology; D013270:Stomach / Q000187:drug effects*
chemical_list: D002109:Caffeic Acids; D002800:Cholinesterase Inhibitors; D005765:Gastrointestinal Agents; C008446:5-methylfurtrethonium; D009116:Muscarine; D006632:Histamine; D010830:Physostigmine; D000110:Acetylcholinesterase; D010418:Pentagastrin; C055494:caffeic acid phenethyl ester; D009543:Nifedipine; D010626:Phenylethyl Alcohol; D011188:Potassium; D015056:1-Methyl-3-isobutylxanthine